FDA clears Evolva’s IND for EV-077 in influenza

29-Mar-2011 - Switzerland

Evolva Holding SA announced that the US Food and Drug Administration (FDA) has cleared Evolva’s request to test EV-077 in man, under an Investigational New Drug (IND) application for influenza.

Neil Goldsmith, CEO and Managing Director of Evolva commented: “This regulatory clearance by the FDA is an important milestone in the development of EV-077. In preclinical testing, EV-077 has shown potential as prophylaxis and treatment of various viral infections. We believe the compound could have significant potential against influenza and in bio-defence.”

Evolva has entered into discussions with potential partners regarding the further development and marketing of the compound. Evolva owns the rights to all intellectual property surrounding EV-077.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance